Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process
Authors:
Open Access
- 4 August 2025
- journal article
- Published by Elsevier in The Lancet HIV
- Vol. 12 (9) , e649-e659
Abstract
No abstract availableKeywords
Funding Information
- Queen Mary University of London
- ViiV Healthcare UK
This publication has 15 references indexed in Scilit:
- Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA PanelJAMA, 2025
- Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical SettingsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2024
- Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)HIV Medicine, 2024
- Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trialThe Lancet Infectious Diseases, 2024
- Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority StudyClinical Infectious Diseases, 2023
- BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022HIV Medicine, 2022
- Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation‐effectiveness studyJournal of the International AIDS Society, 2022
- Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyThe Lancet HIV, 2021
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialThe Lancet HIV, 2020
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014